A phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase (CML-CP) Patients who achieve and sustain MR4.5 after switching to nilotinib
The purpose of this study is to learn if the study drug, nilotinib, can be safely stopped being taken with no return of CML in patients who responded well on the treatment in the past.
chronic myeloid leukemia (CML)
Patients with chronic myeloid leukemia (CML) who have been on imatinib treatment for at least 1 year prior to study entry and have only a very small amount of leukemia cells remaining are eligible for the study.
18 - 100
Healthy Volunteers Needed
Duration of Participation
up to 364 weeks or 7 years
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Novartis Pharmaceuticals, Inc.